Adipose Stem Cells Isolated From Diabetic Mice Improve Cutaneous Wound Healing In Streptozotocin-Induced Diabetic Mice

The study by An et al. from 2020 investigated the therapeutic potential of adipose-derived mesenchymal stem cells (ASCs) from type 1 diabetic (T1D) mice in enhancing wound healing in streptozotocin-induced diabetic mice. The findings revealed that both T1D and control ASCs had similar characteristics in terms of cell surface marker expression, proliferation, and differentiation into various cell types. Despite T1D ASCs secreting less transforming growth factor B1 (TGF-B1), they were as effective as control ASCs in promoting wound closure, hair follicle regeneration, collagen expression, and angiogenesis, as well as reducing IL-6 expression in wound tissues. The study concluded that T1D ASCs are a viable option for improving cutaneous wound healing in diabetic recipients, as they can accelerate the process through fibroblast growth and migration, skin angiogenesis, and differentiation into fibroblasts and endothelial cells. The exact number of mice used in the study was not specified in the summary provided.